Robert Kamen
Advisory Partner at Third Rock Ventures
Sudbury, Massachusetts
Overview
Work Experience
Advisory Partner
2022 - Current
We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine - where transformational science meets operational reality - providing the best opportunity to make a dramatic difference in patients' lives.
Board Member
2015
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with research and manufacturing facilities in Shanghai and Suzhou. With our unique and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that is able to generate bispecific molecules with antibody-like properties, we are creating a pipeline of novel therapeutics focused around immuno-oncology and other disease areas with high unmet need..
Member Board of Directors
2016
Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.
Member Board of Directors
2020
HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.
Board of Directors
2013
Jounce is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce was launched by Third Rock Ventures in 2013.
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Raised $194,249,995.00 from Casdin Capital, Foresite Capital, Omega Funds, Wellington Management, Nextech Invest, Redmile Group, Cormorant Asset Management, Inbio Ventures and Pharmstandard.
Venture Partner
2018 - 2021
Entrepreneur In Residence
2010 - 2017
Board Member
2006 - 2020
Together with our 2800 members and 200 volunteers, we... - Conserve and care for over 4300 acres of fields, forests, and farms in the 36 communities surrounding the Assabet, Sudbury, and Concord Rivers. - Maintain more than 55 miles of hiking trails. - Help friends and neighbors connect with nature through our events, programs, and outings. - Assist local organizations in their efforts to protect the region’s most important natural areas.
Sudbury Valley Trustees works to protect natural areas and farmland for wildlife and people.
Board Member
2015 - 2020
NEON Therapeutics was focused on unlocking the full potential of the immune system to recognize and attack cancer through therapies that target neoantigens. BioNTech acquired Neon in 2020 to strengthen its global leadership position in T cell therapies
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Raised $161,000,000.00 from Hillhouse Investment, ArrowMark Partners, Casdin Capital, Nextech Invest, Access Industries, Wellington Management, Inbio Ventures, Partner Fund Management, Fidelity and Partner Fund Management.
Board of Directors
2009 - 2019
Lycera’s mission was to develop new classes of oral immune modulators that can selectively suppress or activate the immune system, with the potential to transform the treatment of serious immune-related diseases often reliant on the use of injectable agents.
Board Member
2007 - 2016
Harbour Antibodies BV developed novel transgenic mouse antibody platforms for the production of either conventional human antibodies (H2L2) or human heavy chain only antibodies (HCAbs, which are devoid of light chains). It was acquired by Harbour Biomed in 2016.